

Newly Identified Events in the RE-LY Trial

New England Journal of Medicine

363, 1875-1876

DOI: [10.1056/nejmc1007378](https://doi.org/10.1056/nejmc1007378)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Treatments for stroke prevention in atrial fibrillation: A network meta-analysis and indirect comparisons versus dabigatran etexilate. <i>Thrombosis and Haemostasis</i> , 2010, 104, 1106-1115.	1.8	98
2	Oral aspirin appears to be effective for preventing severe skin burning related to tacrolimus ointment use. <i>Reactions Weekly</i> , 2010, &NA;, 2.	0.0	0
3	Dabigatran Etexilate. <i>American Journal of Cardiovascular Drugs</i> , 2011, 11, 57-72.	1.0	36
4	Dabigatran etexilate: a guide to its use in the prevention of thromboembolic disorders. <i>Drugs and Therapy Perspectives</i> , 2011, 27, 1-8.	0.3	0
5	Assess underlying risks when choosing a treatment to prevent strokes in patients with atrial fibrillation. <i>Drugs and Therapy Perspectives</i> , 2011, 27, 14-17.	0.3	0
6	Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 279-286.	0.6	15
7	Dabigatran Etexilate. <i>Circulation</i> , 2011, 123, 1436-1450.	1.6	340
8	2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on) Tj ETQq1,1,0.784314 rgBT / Overlock 1	0.3	114
9	2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on) Tj ETQq0,0,0 rgBT / Overlock 1	1.2	196
10	Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. <i>Thrombosis and Haemostasis</i> , 2011, 106, 968-977.	1.8	320
11	Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective. <i>Thrombosis and Haemostasis</i> , 2011, 105, 908-919.	1.8	185
12	Spotlight on Dabigatran Etexilate in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation. <i>Drugs and Aging</i> , 2011, 28, 415-419.	1.3	1
13	Antithrombotic therapy in nonvalvular atrial fibrillation: A narrative review. <i>Revista Portuguesa De Cardiologia</i> , 2011, 30, 905-924.	0.2	4
14	Dabigatran etexilate: A novel oral direct thrombin inhibitor. <i>American Journal of Health-System Pharmacy</i> , 2011, 68, 1506-1519.	0.5	49
15	Dabigatran Etexilate: A Novel Oral Thrombin Inhibitor for Thromboembolic Disease. <i>Annals of Pharmacotherapy</i> , 2011, 45, 603-614.	0.9	13
16	II. Cerebral Infarction/Transient Ischemic Attack (TIA). <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2011, 20, S31-S73.	0.7	56
17	Antithrombotic therapy in nonvalvular atrial fibrillation: A narrative review. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2011, 30, 905-924.	0.2	3
18	Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2011, 154, 570.	2.0	17

#	ARTICLE	IF	CITATIONS
19	Fast atrial fibrillation and caecal volvulus - a case report and evidence based management. BMJ Case Reports, 2011, 2011, bcr1020114982-bcr1020114982.	0.2	1
20	DABIGATRAN ETEXILATE FOR PREVENTION OF CARDIOEMBOLIC COMPLICATIONS IN NONVALVULAR ATRIAL FIBRILLATION: HOW TO DO THE INTERVENTION MORE EFFECTIVE AND SAFER. Rational Pharmacotherapy in Cardiology, 2011, 7, 757-764.	0.3	0
21	Dabigatran and other oral antithrombotic agents for the prevention of stroke in patients with atrial fibrillation. Research Reports in Clinical Cardiology, 2011, , 71.	0.2	1
22	ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: NEW DATA AND NEW HORIZONS. Rational Pharmacotherapy in Cardiology, 2011, 7, 75-81.	0.3	0
23	Response to Letter by StÅrllberger et al Regarding Article, "Stroke Risk and Antithrombotic Strategies in Atrial Fibrillation". Stroke, 2011, 42, .	1.0	0
24	Clinical trials of direct thrombin and factor Xa inhibitors in atrial fibrillation. Current Opinion in Cardiology, 2011, 26, 294-299.	0.8	7
25	New Anticoagulants for Atrial Fibrillation: The Beginning of a A New Era in Stroke Prevention. Canadian Journal of Neurological Sciences, 2011, 38, 777-782.	0.3	0
26	Oral anticoagulation: A review of the current and emerging therapies. JAAPA: Official Journal of the American Academy of Physician Assistants, 2011, 24, 60-66.	0.1	4
27	Liver Transplantation From Donors With Acute Intermittent Porphyria. Annals of Internal Medicine, 2011, 154, 571.	2.0	60
28	Efficacy and Safety of Dabigatran vs. Warfarin in Patients With Atrial Fibrillation - Sub-Analysis in Japanese Population in RE-LY Trial -. Circulation Journal, 2011, 75, 800-805.	0.7	107
29	Antithrombotic Therapy in Atrial Fibrillation - Evaluation and Positioning of New Oral Anticoagulant Agents -. Circulation Journal, 2011, 75, 1539-1547.	0.7	53
30	Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS_2 Score: A Subgroup Analysis of the RE-LY Trial. Annals of Internal Medicine, 2011, 155, 660.	2.0	181
32	Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation. Annals of Internal Medicine, 2011, 154, 570.	2.0	3
33	Direct thrombin inhibitors. British Journal of Clinical Pharmacology, 2011, 72, 581-592.	1.1	209
34	New Anticoagulants for Prevention of Stroke in Patients with Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2011, 22, 948-955.	0.8	19
35	Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. Journal of Thrombosis and Haemostasis, 2011, 9, 12-19.	1.9	81
36	The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism. , 2011, 130, 46-58.		90
37	New and Emerging Anticoagulant Therapy for Atrial Fibrillation and Acute Coronary Syndrome. Pharmacotherapy, 2011, 31, 975-1016.	1.2	32

#	ARTICLE	IF	CITATIONS
38	Novel Oral Anticoagulants and Their Role in Clinical Practice. <i>Pharmacotherapy</i> , 2011, 31, 1175-1191.	1.2	37
39	Dabigatran Etexilate in Clinical Practice: Confronting Challenges to Improve Safety and Effectiveness. <i>Pharmacotherapy</i> , 2011, 31, 1232-1249.	1.2	31
40	Contemporary Management of Transient Ischemic Attack: Role of the Pharmacist. <i>Pharmacotherapy</i> , 2011, 31, 193-213.	1.2	4
41	Place of Dabigatran in Contemporary Pharmacotherapy. <i>Pharmacotherapy</i> , 2011, 31, 335-337.	1.2	5
42	2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Tj ETQq0 0 0 rgBT /Overlock 1	1.6	400
43	What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?. <i>Thrombosis and Haemostasis</i> , 2011, 105, 574-578.	1.8	60
44	Dabigatran in atrial fibrillation: pharmacology and clinical trials. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2011, 32, 173-180.	0.6	7
46	Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation. <i>Advances in Therapy</i> , 2011, 28, 460-472.	1.3	15
47	Should Dabigatran replace warfarin for stroke prevention in AF?. <i>Drug and Therapeutics Bulletin</i> , 2011, 49, 114-117.	0.3	5
48	Atrial fibrillation and primary stroke prevention. <i>Nursing Standard (Royal College of Nursing (Great Tj ETQq1 1 0.784314 rgBT /Overlock 0,1 4</i>	0.1	4
50	Recommendations for stroke: 2010. <i>Cmaj</i> , 2011, 183, 1627.3-1629.	0.9	0
53	Dabigatran. <i>Critical Pathways in Cardiology</i> , 2011, 10, 117-127.	0.2	11
54	Approved Uses of Dabigatran Etexilate as an Anticoagulant. <i>Journal of Pharmacy Technology</i> , 2011, 27, 258-265.	0.5	0
55	Dilating pupils. <i>Cmaj</i> , 2011, 183, 1629.2-1629.	0.9	0
56	Efficacy and safety of novel anticoagulants compared with established agents. <i>Therapeutic Advances in Hematology</i> , 2011, 2, 175-195.	1.1	13
57	Apixaban in Atrial Fibrillation. <i>Stroke</i> , 2011, 42, 2376-2378.	1.0	4
58	Update on anti-coagulation in atrial fibrillation. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2011, 104, 747-760.	0.2	6
59	The Relative Cost-Effectiveness of Anticoagulants. <i>Circulation</i> , 2011, 123, 2519-2521.	1.6	33

#	ARTICLE	IF	CITATIONS
60	Dabigatran. Hospital Pharmacy, 2011, 46, 196-207.	0.4	1
61	Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. European Heart Journal, 2011, 32, 1968-1976.	1.0	61
63	Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ: British Medical Journal, 2011, 343, d6333-d6333.	2.4	137
64	Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial. Circulation, 2012, 125, 669-676.	1.6	348
65	A Guidance Pathway for the Selection of Novel Anticoagulants in the Treatment of Atrial Fibrillation. Critical Pathways in Cardiology, 2012, 11, 55-61.	0.2	4
66	Stroke prevention in atrial fibrillation. Current Opinion in Neurology, 2012, 25, 27-35.	1.8	15
67	Current and Future Alternatives to Warfarin for the Prevention of Stroke in Atrial Fibrillation. Critical Pathways in Cardiology, 2012, 11, 45-54.	0.2	1
68	Randomized controlled trials of new oral anticoagulants for stroke prevention in atrial fibrillation. Current Opinion in Cardiology, 2012, 27, 331-339.	0.8	9
69	Direct Thrombin Inhibitorsâ€™ Potential Efficacy in Alzheimerâ€™s Disease. American Journal of Alzheimer's Disease and Other Dementias, 2012, 27, 564-567.	0.9	18
70	New Oral Anticoagulants Should Not Be Used as First-Line Agents to Prevent Thromboembolism in Patients With Atrial Fibrillation. Circulation, 2012, 125, 165-170.	1.6	65
71	New Oral Anticoagulants. , 2012, , .		0
72	Dabigatran. Journal of Cardiovascular Pharmacology and Therapeutics, 2012, 17, 237-247.	1.0	7
73	Dabigatran: Do We Have Sufficient Data?. Archives of Internal Medicine, 2012, 172, 403.	4.3	21
74	Advances in the management of atrial fibrillation. Clinical Medicine, 2012, 12, 544-552.	0.8	0
76	Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 949-957.	0.2	37
77	Emerging Anticoagulant Therapies for Atrial Fibrillation: New Options, New Challenges. Current Medicinal Chemistry, 2012, 19, 4688-4698.	1.2	7
78	The Oral Thrombin Inhibitor Dabigatran: Strengths and Weaknesses. Seminars in Thrombosis and Hemostasis, 2012, 38, 07-15.	1.5	17
79	A Review of Oral Anticoagulants in Patients with Atrial Fibrillation. Postgraduate Medicine, 2012, 124, 7-16.	0.9	74

#	ARTICLE	IF	CITATIONS
80	Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. <i>Heart</i> , 2012, 98, 573-578.	1.2	106
81	Dabigatran for the prevention of stroke in atrial fibrillation: is RE-LY reliable?. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1087-1090.	0.9	1
82	Novel drugs for oral anticoagulation pharmacotherapy. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 473-488.	0.6	6
84	New Oral Anticoagulants for Atrial Fibrillation. <i>Circulation</i> , 2012, 126, 133-137.	1.6	23
85	The Effects of Direct Thrombin Inhibition with Dabigatran on Plaque Formation and Endothelial Function in Apolipoprotein E-Deficient Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 343, 253-257.	1.3	88
86	New anticoagulants in atrial fibrillation: an update for clinicians. <i>Therapeutic Advances in Chronic Disease</i> , 2012, 3, 37-45.	1.1	6
87	Stroke Prevention in Atrial Fibrillation: Where are We Now?. <i>Clinical Medicine Insights: Cardiology</i> , 2012, 6, CMC.S8976.	0.6	9
88	Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation. <i>Pharmaceuticals</i> , 2012, 5, 155-168.	1.7	7
89	Optimal thromboprophylaxis following bioprosthetic aortic valve replacement: still a matter of debate?. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2012, 15, 109-114.	0.5	11
90	Novel anticoagulants in atrial fibrillation stroke prevention. <i>Therapeutic Advances in Chronic Disease</i> , 2012, 3, 123-136.	1.1	16
91	Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database. <i>BMJ Open</i> , 2012, 2, e001768.	0.8	48
92	Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation. <i>Stroke</i> , 2012, 43, 3442-3453.	1.0	248
93	Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents. <i>Europace</i> , 2012, 14, 312-324.	0.7	32
94	Stroke Prevention in Atrial Fibrillation: Concepts and Controversies. <i>Current Cardiology Reviews</i> , 2012, 8, 290-301.	0.6	12
95	Oral IIa and Xa Inhibitors for Prevention of Stroke in Atrial Fibrillation: Clinical Studies and Regulatory Considerations. <i>Current Clinical Pharmacology</i> , 2012, 7, 166-174.	0.2	3
96	Atrial Fibrillation in Acute St-Elevation Myocardial Infarction: Clinical and Prognostic Features. <i>Current Cardiology Reviews</i> , 2012, 8, 281-289.	0.6	25
97	Hypertension and atrial fibrillation. <i>Journal of Hypertension</i> , 2012, 30, 239-252.	0.3	177
98	Stroke prevention in atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2012, 13, 73-85.	0.6	11

#	ARTICLE	IF	CITATIONS
101	Dabigatran etexilate for the prevention of stroke in patients with nonvalvular atrial fibrillation. <i>Clinical Practice (London, England)</i> , 2012, 9, 629-637.	0.1	0
102	A New Era of Antithrombotic Therapy in Patients With Atrial Fibrillation. <i>American Journal of the Medical Sciences</i> , 2012, 344, 128-135.	0.4	2
103	New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2649-2661.	0.9	8
104	Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1830-1840.	1.9	89
105	Filling the gap between science & clinical practice: Prevention of stroke recurrence. <i>Thrombosis Research</i> , 2012, 129, 3-8.	0.8	14
106	Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. <i>Lancet Neurology</i> , The, 2012, 11, 1066-1081.	4.9	75
107	Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. <i>Thrombosis and Haemostasis</i> , 2012, 108, 672-682.	1.8	57
108	Dabigatran for stroke prevention in atrial fibrillation. <i>Hamostaseologie</i> , 2012, 32, 216-220.	0.9	2
109	Vitamin K antagonists. <i>Hamostaseologie</i> , 2012, 32, 249-257.	0.9	8
110	A New Generation of Oral Direct Anticoagulants. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 569-574.	1.1	31
111	Management of Atrial Fibrillation: Direct Factor IIa and Xa Inhibitors or "Warfarin Shotgun". <i>Mount Sinai Journal of Medicine</i> , 2012, 79, 705-720.	1.9	1
113	Dabigatran etexilate: Another Double-Edged Drug?. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 361-364.	1.3	1
114	Prevention of stroke in patients with atrial fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2012, 35, 19-27.	0.6	2
115	Pharmacokinetic evaluation of argatroban for the treatment of acute coronary syndrome. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 1483-1493.	1.5	1
116	Análisis coste-efectividad de dabigatrán para la prevención de ictus y embolia sistémica en fibrilación auricular no valvular en España. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 901-910.	0.6	76
117	Evidencias clínicas del estudio RE-LY en la prevención de ictus y tromboembolia por fibrilación auricular. <i>Revista Espanola De Cardiologia Suplementos</i> , 2012, 12, 25-30.	0.2	2
119	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. <i>Europace</i> , 2012, 14, 1385-1413.	0.7	2,319
120	Dabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1101-1111.	0.9	9

#	ARTICLE	IF	CITATIONS
121	Efficacia e sicurezza dei nuovi farmaci anticoagulanti orali rispetto al warfarin nella profilassi cardioembolica del paziente con fibrillazione atriale non valvolare. Pi�1 luci che ombre. Italian Journal of Medicine, 2012, 6, 153-169.	0.2	0
122	Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. BMJ, The, 2012, 345, e7097-e7097.	3.0	110
123	Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran. Stroke, 2012, 43, 1511-1517.	1.0	385
124	Use of anticoagulants in elderly patients. Thrombosis Research, 2012, 129, 107-115.	0.8	57
125	Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation. Thrombosis Research, 2012, 129, 9-16.	0.8	8
126	Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: A review of the literature. Thrombosis Research, 2012, 129, 392-400.	0.8	56
127	Impact of dabigatran on a large panel of routine or specific coagulation assays. Thrombosis and Haemostasis, 2012, 107, 985-997.	1.8	321
128	A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The Randomized, phase II study to Evaluate the sAFety and pharmacokinetics of oral dabiGatran etexilate in patients after heart valve replacemeNt (RE-ALIGN). American Heart Journal, 2012, 163, 931-937.e1.	1.2	164
129	Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) Versus Warfarin in Patients With Atrial Fibrillation. American Journal of Cardiology, 2012, 110, 453-460.	0.7	399
130	Dabigatran and Factor Xa Inhibitors for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation. Journal of Stroke and Cerebrovascular Diseases, 2012, 21, 165-173.	0.7	12
131	Supporting Treatment decision making to Optimise the Prevention of STROKE in Atrial Fibrillation: The STOP STROKE in AF study. Protocol for a cluster randomised controlled trial. Implementation Science, 2012, 7, 63.	2.5	2
132	An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thrombosis and Haemostasis, 2012, 108, 476-484.	1.8	140
133	Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles?. British Journal of Clinical Pharmacology, 2012, 74, 734-740.	1.1	15
134	Dabigatran Association With Higher Risk of Acute Coronary Events. Archives of Internal Medicine, 2012, 172, 397.	4.3	394
135	Dabigatran Etexilate. Pharmacoeconomics, 2012, 30, 841-855.	1.7	16
136	Dabigatran and risk of myocardial infarction. Nature Reviews Cardiology, 2012, 9, 260-262.	6.1	30
137	New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes. Journal of the American College of Cardiology, 2012, 59, 1413-1425.	1.2	257
138	Antithrombotic Strategies to Reduce Adverse Clinical Outcomes in Patients With Acute Coronary Syndrome. American Journal of Cardiology, 2012, 110, 1200-1206.	0.7	5

#	ARTICLE	IF	CITATIONS
139	Dabigatran in Clinical Practice. <i>Clinical Therapeutics</i> , 2012, 34, 2051-2060.	1.1	14
140	Evaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopedic surgery: Findings from four Phase 3 trials. <i>Thrombosis Research</i> , 2012, 130, 396-402.	0.8	12
141	New oral anticoagulants for stroke prevention in atrial fibrillation: Evidence from phase III clinical trials. <i>Journal of Indian College of Cardiology</i> , 2012, 2, 112-116.	0.1	0
142	Fact-finding survey of antithrombotic treatment for prevention of cerebral and systemic thromboembolism in patients with non-valvular atrial fibrillation in 9 countries of the Asia-Pacific region. <i>Journal of Arrhythmia</i> , 2012, 28, 41-55.	0.5	3
143	Stroke: management and prevention. <i>Medicine</i> , 2012, 40, 490-499.	0.2	9
144	Head-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: Whatâ€™s next?. <i>Thrombosis and Haemostasis</i> , 2012, 108, 407-409.	1.8	26
145	Use of New-Generation Oral Anticoagulant Agents in Patients Receiving Antiplatelet Therapy After an Acute Coronary Syndrome. <i>Archives of Internal Medicine</i> , 2012, 172, 1537.	4.3	67
147	Cost-effectiveness of Dabigatran for Stroke Prevention in Non-valvular Atrial Fibrillation in Spain. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 901-910.	0.4	39
148	Balancing Efficacy and Bleeding Risk in the Prevention of Stroke Due to Atrial Fibrillation with Newer Oral Anticoagulants. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2012, 28, 129-143.	0.3	2
149	Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism. <i>Annals of Internal Medicine</i> , 2012, 157, 796.	2.0	177
150	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. <i>European Heart Journal</i> , 2012, 33, 2719-2747.	1.0	3,144
151	New Anticoagulants for Stroke Prophylaxis in Atrial Fibrillation. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 287-294.	1.0	8
152	Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. <i>Journal of Medical Economics</i> , 2012, 15, 776-785.	1.0	83
153	Cost-Effectiveness of Dabigatran versus Genotype-Guided Management of Warfarin Therapy for Stroke Prevention in Patients with Atrial Fibrillation. <i>PLoS ONE</i> , 2012, 7, e39640.	1.1	58
154	Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice. <i>Thrombosis and Haemostasis</i> , 2012, 107, 838-847.	1.8	201
155	Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban. <i>Thrombosis</i> , 2012, 2012, 1-10.	1.4	12
157	Atrial fibrillation 2: assessment and diagnosis. <i>Practice Nursing</i> , 2012, 23, 70-77.	0.1	0
158	Efficacy and safety of new oral anticoagulants compared with warfarin in cardioembolic prophylaxis of patients with non valvular atrial fibrillation. More lights than shadows. <i>Italian Journal of Medicine</i> , 0, , .	0.2	3

#	ARTICLE	IF	CITATIONS
159	Dabigatran in Atrial Fibrillation: New Kid on the Block. Canadian Pharmacists Journal, 2012, 145, 83-87.e1.	0.4	2
160	New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders. Vascular Health and Risk Management, 2012, 8, 45.	1.0	12
161	Dabigatran for the Prevention of Thromboembolic Complications in the Elderly: A RE-LY-able Alternative to Warfarin?. The Consultant Pharmacist, 2012, 27, 445-452.	0.4	1
163	Direct thrombin inhibitors in cardiovascular disease. Nature Reviews Cardiology, 2012, 9, 402-414.	6.1	30
164	Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation. Journal of the American College of Cardiology, 2012, 60, 738-746.	1.2	272
165	Antiplatelet Drugs. Chest, 2012, 141, e89S-e119S.	0.4	318
166	New Frontiers for Stroke Prevention in Atrial Fibrillation. Cerebrovascular Diseases, 2012, 33, 199-208.	0.8	24
167	Comparative Efficacy and Safety of New Oral Anticoagulants in Patients With Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 480-486.	0.9	128
168	New anticoagulant treatments to protect against stroke in atrial fibrillation. Heart, 2012, 98, 1341-1347.	1.2	39
169	Atrial Fibrillation and Vascular Disease—A Bad Combination. Clinical Cardiology, 2012, 35, 15-20.	0.7	27
170	Anticoagulant therapy for patients with ischaemic stroke. Nature Reviews Neurology, 2012, 8, 319-328.	4.9	28
171	Using Dabigatran in Patients With Stroke. Stroke, 2012, 43, 271-279.	1.0	38
172	Atrial fibrillation and diabetes mellitus. Herz, 2012, 37, 258-263.	0.4	4
175	Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: Focus on Apixaban. Advances in Therapy, 2012, 29, 491-507.	1.3	29
176	Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile. European Journal of Clinical Pharmacology, 2012, 68, 607-616.	0.8	23
177	Anticoagulant management in the cardiovascular setting. Fundamental and Clinical Pharmacology, 2012, 26, 11-15.	1.0	5
178	Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation. Journal of Internal Medicine, 2012, 271, 15-24.	2.7	48
179	Anticoagulation management in clinical practice: Preventing stroke in patients with atrial fibrillation. Heart and Lung: Journal of Acute and Critical Care, 2012, 41, 146-156.	0.8	6

#	ARTICLE	IF	CITATIONS
181	Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. <i>Lancet Neurology</i> , The, 2012, 11, 503-511.	4.9	252
182	New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation. <i>Journal of Internal Medicine</i> , 2012, 271, 554-565.	2.7	26
183	UPLC MS/MS assay for routine quantification of dabigatran " A direct thrombin inhibitor " In human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 58, 152-156.	1.4	58
186	Antithrombotic therapy for stroke prevention in atrial fibrillation and mechanical heart valves. <i>American Journal of Hematology</i> , 2012, 87, S100-7.	2.0	5
187	Promise of Factor Xa Inhibition in Atrial Fibrillation. <i>Current Cardiology Reports</i> , 2012, 14, 70-78.	1.3	3
188	Preventing Cardioembolic Stroke in Atrial Fibrillation with Dabigatran. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 17-23.	2.0	8
190	Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. <i>Thrombosis Journal</i> , 2013, 11, 10.	0.9	141
191	Optimizing the Use of Anticoagulants (Heparins and Oral Anticoagulants) in the Elderly. <i>Drugs and Aging</i> , 2013, 30, 687-699.	1.3	17
192	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1495-1539.	1.2	276
193	Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2013, 37, 223-231.	0.6	33
194	Novel oral anticoagulants in non-valvular atrial fibrillation. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 115-129.	0.7	27
195	New oral anticoagulants after acute coronary syndrome. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 141-150.	0.7	2
196	New oral anticoagulants in elderly patients. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 215-224.	0.7	60
197	Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 225-237.	0.7	27
198	Novel Oral Anticoagulants for Atrial Fibrillation. <i>Current Atherosclerosis Reports</i> , 2013, 15, 344.	2.0	14
199	A Comparative Analysis of Models Used to Evaluate the Cost-Effectiveness of Dabigatran Versus Warfarin for the Prevention of Stroke in Atrial Fibrillation. <i>Pharmacoeconomics</i> , 2013, 31, 589-604.	1.7	14
200	Target specific oral anticoagulants in the management of thromboembolic disease in the elderly. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 203-211.	1.0	3
201	Practical issues, limitations, and periprocedural management of the NOACs. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 212-222.	1.0	29

#	ARTICLE	IF	CITATIONS
202	Dabigatran Does Not Prolong the QT Interval with Supratherapeutic Exposure: a Thorough QT Study in Healthy Subjects. <i>Clinical Drug Investigation</i> , 2013, 33, 333-342.	1.1	6
203	Dabigatran versus Warfarin in Patients with Mechanical Heart Valves. <i>New England Journal of Medicine</i> , 2013, 369, 1206-1214.	13.9	1,201
204	Cross-trial comparisons: A source of confusion, use, or both in the management of patients with atrial fibrillation?. <i>American Heart Journal</i> , 2013, 165, 882-892.	1.2	3
206	Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation. <i>International Journal of Clinical Practice</i> , 2013, 67, 516-526.	0.8	20
208	2013 ACCF/AHA Guideline for the Management of Heart Failure. <i>Circulation</i> , 2013, 128, e240-327.	1.6	2,335
210	The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. <i>Circulation</i> , 2013, 128, 237-243.	1.6	195
211	Novel Therapeutics for Thromboprophylaxis in Nonvalvular Atrial Fibrillation. <i>Drug Development Research</i> , 2013, 74, 485-491.	1.4	0
212	Oral Anticoagulants to Reduce the Risk of Stroke in Atrial Fibrillation: How Should a Clinician Choose?. <i>Clinical Cardiology</i> , 2013, 36, 663-670.	0.7	3
213	Do open label blinded outcome studies of novel anticoagulants versus warfarin have equivalent validity to those carried out under double-blind conditions?. <i>Thrombosis and Haemostasis</i> , 2013, 109, 497-503.	1.8	19
214	The hidden costs of anticoagulation in hospitalized patients with non-valvular atrial fibrillation. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1119-1133.	0.9	5
215	Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium. <i>Journal of Medical Economics</i> , 2013, 16, 407-414.	1.0	30
216	The Efficacy and Safety of Oral Anticoagulants in Warfarin-Suitable Patients With Nonvalvular Atrial Fibrillation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2013, 19, 619-631.	0.7	40
217	New Oral Anticoagulants: Comparative Pharmacology with Vitamin K Antagonists. <i>Clinical Pharmacokinetics</i> , 2013, 52, 69-82.	1.6	172
218	Ineligibility for Anticoagulation in Patients with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2013, 126, 105-111.	0.6	10
219	New Avenues for Anticoagulation in Atrial Fibrillation. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 93, 68-77.	2.3	21
220	Bleeding of New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials. <i>Cardiovascular Drugs and Therapy</i> , 2013, 27, 23-35.	1.3	30
221	Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 295-301.	1.0	59
223	Economic evaluation of dabigatran for stroke prevention in patients with non-valvular atrial fibrillation. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2013, 32, 557-565.	0.2	17

#	ARTICLE	IF	CITATIONS
224	Impact of Atrial Fibrillation on Outcomes in Heart Failure. <i>Heart Failure Clinics</i> , 2013, 9, 437-449.	1.0	2
225	Antithrombotic activity of HY023016, a novel Dabigatran prodrug evaluated in animal thrombosis models. <i>Thrombosis Research</i> , 2013, 131, 425-435.	0.8	11
226	Evidencias sobre el coste económico de los nuevos anticoagulantes. <i>Semergen</i> , 2013, 39, 30-35.	0.2	0
227	Atrial Fibrillation: What's New?. <i>Journal for Nurse Practitioners</i> , 2013, 9, 400-401.	0.4	0
229	Review of Recently Approved Alternatives to Anticoagulation with Warfarin for Emergency Clinicians. <i>Journal of Emergency Medicine</i> , 2013, 45, 143-149.	0.3	15
230	Actualización detallada de las guías de la ESC para el manejo de la fibrilación auricular de 2012. <i>Revista Espanola De Cardiologia</i> , 2013, 66, 54.e1-54.e24.	0.6	14
231	The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation. <i>Journal of Arrhythmia</i> , 2013, 29, 190-200.	0.5	69
232	Managing Blunt Trauma in Patients Receiving Dabigatran Etxilate: Case Study and Review of the Literature. <i>Journal of Emergency Nursing</i> , 2013, 39, 302-308.	0.5	4
233	Long-term clinical course of acute pulmonary embolism. <i>Blood Reviews</i> , 2013, 27, 185-192.	2.8	28
234	Novel oral anticoagulants for stroke prevention in atrial fibrillation: Key trial findings and clinical implications. <i>Trends in Cardiovascular Medicine</i> , 2013, 23, 128-134.	2.3	3
235	Anticoagulation in heart failure: current status and future direction. <i>Heart Failure Reviews</i> , 2013, 18, 797-813.	1.7	28
236	Implications of new anticoagulants in primary practice. <i>International Journal of Clinical Practice</i> , 2013, 67, 139-156.	0.8	17
237	Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 129-141.	0.6	36
238	Oral Anticoagulation in Elderly Adults with Atrial Fibrillation: Integrating New Options with Old Concepts. <i>Journal of the American Geriatrics Society</i> , 2013, 61, 143-150.	1.3	26
239	Managing anticoagulation for atrial fibrillation: current issues and future strategies. <i>Journal of Internal Medicine</i> , 2013, 273, 31-41.	2.7	9
240	The novel anticoagulants: The surgeons' prospective. <i>Surgery</i> , 2013, 153, 303-307.	1.0	8
241	Clinical update on the management of atrial fibrillation. <i>Pharmacotherapy</i> , 2013, 33, 422-446.	1.2	15
242	Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2013, 368, 709-718.	13.9	868

#	ARTICLE	IF	CITATIONS
243	Clinical trials with new oral anticoagulants. <i>Hamostaseologie</i> , 2013, 33, 62-70.	0.9	9
244	Efficacy and Safety of Dabigatran Etexilate and Warfarin in "Real-World" Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2264-2273.	1.2	387
245	Improving the use of direct oral anticoagulants in atrial fibrillation. <i>European Journal of Internal Medicine</i> , 2013, 24, 288-294.	1.0	11
246	Target-specific oral anticoagulants in atrial fibrillation: results of phase III trials and comments on sub-analyses. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 155-162.	1.0	1
247	Dabigatran, intracranial hemorrhage, and the neurosurgeon. <i>Neurosurgical Focus</i> , 2013, 34, E7.	1.0	14
248	Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care. <i>International Journal of Clinical Practice</i> , 2013, 67, 647-655.	0.8	4
249	Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 62, 900-908.	1.2	59
250	2013 ACCF/AHA Guideline for the Management of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 62, e147-e239.	1.2	7,017
251	Selection of Medications to Prevent Stroke Among Individuals With Atrial Fibrillation. <i>Current Treatment Options in Neurology</i> , 2013, 15, 583-592.	0.7	0
252	Transitions of care in anticoagulated patients. <i>Journal of Multidisciplinary Healthcare</i> , 2013, 6, 215.	1.1	18
253	Oral bioavailability of dabigatran etexilate (radaxa [®]) after co-medication with verapamil in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1053-1062.	1.1	135
254	Impact of double-blind vs. open study design on the observed treatment effects of new oral anticoagulants in atrial fibrillation: a meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1240-1250.	1.9	15
255	Stroke prevention in patients with atrial fibrillation - anticoagulation strategy 2012. <i>Cor Et Vasa</i> , 2013, 55, e95-e100.	0.1	0
256	Antithrombotic Therapy in Atrial Fibrillation. <i>Hospital Medicine Clinics</i> , 2013, 2, e1-e31.	0.2	0
257	Assessing the impact of dabigatran and warfarin on health-related quality of life: Results from an RE-LY sub-study. <i>International Journal of Cardiology</i> , 2013, 168, 2540-2547.	0.8	50
258	Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. <i>Clinical Research in Cardiology</i> , 2013, 102, 399-412.	1.5	179
259	Cost-Effectiveness of Oral Anticoagulants for Treatment of Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 724-731.	0.9	71
260	Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation. <i>Stroke</i> , 2013, 44, 1676-1681.	1.0	233

#	ARTICLE	IF	CITATIONS
261	The Pharmacology and Therapeutic Use of Dabigatran Etxilate. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 1-13.	1.0	22
262	Eleven Commonly Asked Questions About Ischemic Stroke. <i>Topics in Stroke Rehabilitation</i> , 2013, 20, 93-100.	1.0	1
263	Prescribing patterns of novel oral anticoagulants following regulatory approval for atrial fibrillation in Ontario, Canada: a population-based descriptive analysis. <i>CMAJ Open</i> , 2013, 1, E115-E119.	1.1	68
264	Recent Advances in Antithrombotic Therapy for Stroke Prevention in Patients With Atrial Fibrillation. <i>Hospital Practice (1995)</i> , 2013, 41, 49-60.	0.5	0
265	Direct Thrombin and Factor Xa Inhibition for Stroke Prevention in Patients With Atrial Fibrillation. <i>Hospital Practice (1995)</i> , 2013, 41, 26-36.	0.5	1
266	Alternatives to Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation: A Look Back at the State of the Field in 2012. <i>Postgraduate Medicine</i> , 2013, 125, 146-157.	0.9	0
267	Advances in Stroke Prevention in Atrial Fibrillation: Enhanced Risk Stratification Combined With the Newer Oral Anticoagulants. <i>Clinical Cardiology</i> , 2013, 36, 312-322.	0.7	4
268	Novel oral anticoagulants for the prevention and treatment of thromboembolism. <i>Future Cardiology</i> , 2013, 9, 849-861.	0.5	3
269	Stop the clots, but at what cost? Pharmacoeconomics of dabigatran etexilate for the prevention of stroke in subjects with atrial fibrillation: a systematic literature review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 29-42.	0.7	7
270	Novel Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation. <i>Hospital Practice (1995)</i> , 2013, 41, 37-48.	0.5	3
271	New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: More Choices Bring More Challenges. <i>Hospital Pharmacy</i> , 2013, 48, 366-371.	0.4	2
272	Transitions of Care in Patients Receiving Oral Anticoagulants. <i>Journal of Cardiovascular Nursing</i> , 2013, 28, 54-65.	0.6	4
273	Can dabigatran improve blood pressure control?. <i>Future Cardiology</i> , 2013, 9, 321-323.	0.5	1
274	Dabigatran associated with increased risk of acute coronary events. <i>Evidence-Based Medicine</i> , 2013, 18, e9-e9.	0.6	0
275	Clinical Judgment When Using Coagulation Tests during Direct Oral Anticoagulant Treatment: A Concise Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 840-846.	1.5	22
276	Novel Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation: Dawn of a New Era. <i>Postgraduate Medicine</i> , 2013, 125, 34-44.	0.9	11
277	Modeling of the Impact on Health Outcomes of the Use of Dabigatran in Patients with Atrial Fibrillation. <i>Cerebrovascular Diseases</i> , 2013, 35, 320-326.	0.8	2
278	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. <i>Circulation</i> , 2013, 128, 1810-1852.	1.6	2,807

#	ARTICLE	IF	CITATIONS
279	Ischemic Stroke and Intestinal Bleeding Under Dabigatran in Metabolic Myopathy. <i>Cardiovascular Therapeutics</i> , 2013, 31, e111-4.	1.1	3
280	Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. <i>European Journal of Heart Failure</i> , 2013, 15, 1053-1061.	2.9	82
282	The place of newer oral anticoagulants in the treatment of patients with non-valvular atrial fibrillation and coronary artery disease. <i>International Journal of Clinical Practice</i> , 2013, 67, 707-709.	0.8	0
283	Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden. <i>European Heart Journal</i> , 2013, 34, 177-183.	1.0	55
284	The need for multicentre cardiovascular clinical trials in Asia. <i>Nature Reviews Cardiology</i> , 2013, 10, 355-362.	6.1	6
285	Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1461-1471.	0.6	2
286	A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 1105-1114.	0.6	7
287	Safety and Efficacy of Adjusted Dose of Rivaroxaban in Japanese Patients With Non-Valvular Atrial Fibrillation. <i>Circulation Journal</i> , 2013, 77, 632-638.	0.7	64
288	Model-based Dose Selection for Phase III Rivaroxaban Study in Japanese Patients with Non-valvular Atrial Fibrillation. <i>Drug Metabolism and Pharmacokinetics</i> , 2013, 28, 59-70.	1.1	92
289	Confirmation of Model-based Dose Selection for a Japanese Phase III Study of Rivaroxaban in Non-valvular Atrial Fibrillation Patients. <i>Drug Metabolism and Pharmacokinetics</i> , 2013, 28, 321-331.	1.1	47
290	Practical approaches to the treatment of atrial fibrillation: focus on stroke prevention using oral anticoagulant drugs. <i>Clinical Practice (London, England)</i> , 2013, 10, 317-332.	0.1	0
294	New atrial fibrillation guidelines: implementation in the clinic. <i>Clinical Practice (London, England)</i> , 2013, 10, 31-38.	0.1	1
295	Oral anticoagulation: a changing practice. <i>Gastrointestinal Nursing</i> , 2013, 11, 22-28.	0.0	0
296	Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. <i>Vascular Health and Risk Management</i> , 2013, 9, 599.	1.0	30
297	New Oral Anticoagulants in Atrial Fibrillation. , 2013, , .		0
298	Is there really misuse and abuse of dabigatran?. <i>Medical Journal of Australia</i> , 2013, 198, 358-359.	0.8	4
299	A new era of stroke prevention in atrial fibrillation: comparing a new generation of oral anticoagulants with warfarin. <i>International Archive of Medicine</i> , 2013, 6, 46.	1.2	14
300	PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION. <i>Rational Pharmacotherapy in Cardiology</i> , 2013, 9, 551-556.	0.3	0

#	ARTICLE	IF	CITATIONS
301	The practical management of bleedings during treatment with direct oral anticoagulants: the emergency reversal therapy. Italian Journal of Medicine, 2013, 7, 48.	0.2	2
302	The Discovery of Dabigatran Etxilate. Frontiers in Pharmacology, 2013, 4, 12.	1.6	52
303	Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups. Thrombosis, 2013, 2013, 1-18.	1.4	154
304	Anticoagulation for Atrial Fibrillation: Is This the End of Warfarin? Not Just Yet. Journal of Angiology, 2013, 2013, 1-7.	0.0	7
305	Oral anticoagulation to reduce risk of stroke in patients with atrial fibrillation: current and future therapies. Clinical Interventions in Aging, 2013, 8, 75.	1.3	24
306	Hemostatic Aspects of Cardiovascular Medicine. , 2013, , 342-394.		0
307	Direct oral anticoagulants in real practice: which doses for which patients. Limitations and bleeding risk compared to vitamin K antagonists. Italian Journal of Medicine, 2013, 7, 41.	0.2	0
308	Direct oral anticoagulants for secondary prevention in patients with non-valvular atrial fibrillation. Italian Journal of Medicine, 2013, 7, 8.	0.2	3
309	ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES. Rational Pharmacotherapy in Cardiology, 2013, 9, 171-176.	0.3	0
310	Editorial (Thematic Issue: Advances in The Therapy of Atrial Fibrillation: Incrementally Progressive But) Tj ETQq1 1 0,784314 rgBT /Ovele 0,6		
311	Twice- or Once-Daily Dosing of Novel Oral Anticoagulants for Stroke Prevention: A Fixed-Effects Meta-Analysis with Predefined Heterogeneity Quality Criteria. PLoS ONE, 2014, 9, e99276.	1.1	33
312	Targeting factor Xa and thrombin: impact on coagulation and beyond. Thrombosis and Haemostasis, 2014, 111, 625-633.	1.8	108
313	A clinician’s perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation – full speed ahead or proceed with caution?. Vascular Health and Risk Management, 2014, 10, 507.	1.0	21
314	Dabigatran and myocardial infarction: a foggy scenario. Vascular Health and Risk Management, 2014, 10, 45.	1.0	0
315	Bleeding Incidence and Real-Life Prescribing Practices with Dabigatran Use in an Acute Care Setting. The Consultant Pharmacist, 2014, 29, 735-740.	0.4	2
316	Dabigatran: patient management in specific clinical settings. Wiener Klinische Wochenschrift, 2014, 126, 503-508.	1.0	6
317	Comparison of the Cost-effectiveness of New Oral Anticoagulants for the Prevention of Stroke and Systemic Embolism in Atrial Fibrillation in a UK Setting. Clinical Therapeutics, 2014, 36, 2015-2028.e2.	1.1	35
319	Stroke Prevention in Patients With Atrial Fibrillation and Renal Dysfunction. Stroke, 2014, 45, 2497-2505.	1.0	13

#	ARTICLE	IF	CITATIONS
320	Current approaches in atrial fibrillation treatment. <i>Dicle Medical Journal</i> , 2014, 41, 614-622.	0.2	1
321	Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US. <i>Current Medical Research and Opinion</i> , 2014, 30, 795-804.	0.9	15
322	Additional Events in the RE-LY Trial. <i>New England Journal of Medicine</i> , 2014, 371, 1464-1465.	13.9	47
324	Cost Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in Two Different European Healthcare Settings. <i>American Journal of Cardiovascular Drugs</i> , 2014, 14, 451-462.	1.0	39
325	A proposal for dose adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 599-609.	1.1	25
326	The trouble with dabigatran. <i>BMJ, The</i> , 2014, 349, g4681-g4681.	3.0	26
327	Practical Considerations for Using Novel Oral Anticoagulants in Patients With Atrial Fibrillation. <i>Clinical Cardiology</i> , 2014, 37, 32-47.	0.7	72
328	Advantages and limitations of the new anticoagulants. <i>Journal of Internal Medicine</i> , 2014, 275, 1-11.	2.7	69
329	Evolving use of new oral anticoagulants for treatment of venous thromboembolism. <i>Blood</i> , 2014, 124, 1020-1028.	0.6	114
330	Incidence, Mortality, and Risk Factors for Oral Anticoagulant-associated Intracranial Hemorrhage in Patients with Atrial Fibrillation. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2014, 23, 2479-2488.	0.7	22
331	Bleeding Rates in Veterans Affairs Patients with Atrial Fibrillation Who Switch from Warfarin to Dabigatran. <i>American Journal of Medicine</i> , 2014, 127, 1179-1185.	0.6	49
332	Dabigatran Use in the Real World. <i>Journal of Pharmacy Practice</i> , 2014, 27, 384-388.	0.5	5
333	Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation. <i>Cardiovascular Drugs and Therapy</i> , 2014, 28, 575-585.	1.3	24
334	Physician's Fear of Anticoagulant Therapy in Nonvalvular Atrial Fibrillation. <i>American Journal of the Medical Sciences</i> , 2014, 348, 513-521.	0.4	46
335	Targeting Therapy to the Fibrin-Mediated Pathophysiology of Acute Coronary Syndrome. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2014, 20, 516-523.	0.7	4
336	Increased risk of myocardial infarction with dabigatran. <i>Journal of Cardiovascular Medicine</i> , 2014, 15, 19-26.	0.6	8
337	Patient outcomes using the European label for dabigatran. <i>Thrombosis and Haemostasis</i> , 2014, 112, 933-942.	1.8	94
338	Dabigatran Etexilate and Risk of Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and All-Cause Mortality: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2014, 3, e000515.	1.6	85

#	ARTICLE	IF	CITATIONS
339	Novel Oral Anticoagulants in Cardiovascular Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 34-44.	1.0	23
340	Protecting the Brain and the Heart. <i>Angiology</i> , 2014, 65, 372-378.	0.8	1
341	The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients. <i>Journal of the American College of Cardiology</i> , 2014, 63, 321-328.	1.2	733
342	Patient Perspectives of Dabigatran: Analysis of Online Discussion Forums. <i>Patient</i> , 2014, 7, 47-54.	1.1	37
343	Presentation, therapy and outcome of patients with ischemic stroke under new oral anticoagulants. <i>Neurologia I Neurochirurgia Polska</i> , 2014, 48, 136-140.	0.6	8
344	Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm. <i>International Journal of Cardiology</i> , 2014, 174, 471-483.	0.8	20
345	Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis. <i>Clinical Drug Investigation</i> , 2014, 34, 9-17.	1.1	53
346	Novel Oral Anticoagulants Versus Warfarin Therapy at Various Levels of Anticoagulation Control in Atrial Fibrillation—A Cost-Effectiveness Analysis. <i>Journal of General Internal Medicine</i> , 2014, 29, 438-446.	1.3	45
347	Warfarin and atrial fibrillation: from ideal to real the warfarin affaire. <i>Thrombosis Journal</i> , 2014, 12, 5.	0.9	39
348	Evidence behind quality of care measures for venous thromboembolism and atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 87-96.	1.0	6
350	Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: A global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. <i>American Heart Journal</i> , 2014, 167, 329-334.	1.2	112
351	Practical Considerations in the Use of Novel Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation. <i>Cardiovascular Therapeutics</i> , 2014, 32, 74-81.	1.1	8
352	Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. <i>Lancet, The</i> , 2014, 383, 955-962.	6.3	3,942
353	Use of novel oral anticoagulants for patients with atrial fibrillation: Systematic review and clinical implications. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2014, 43, 48-59.	0.8	20
354	Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis. <i>Circulation</i> , 2014, 129, 764-772.	1.6	824
355	Atrial Fibrillation Therapy. , 2014, , .		3
356	Novel Oral Anticoagulants for Stroke Prevention in the Geriatric Population. <i>American Journal of Cardiovascular Drugs</i> , 2014, 14, 15-29.	1.0	4
357	Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation. <i>Cardiology Clinics</i> , 2014, 32, 585-599.	0.9	7

#	ARTICLE	IF	CITATIONS
358	Analisi di costo efficacia dei nuovi anticoagulanti orali nella prevenzione dell'ictus in pazienti con fibrillazione atriale non valvolare in Italia. <i>Pharmacoeconomics Italian Research Articles</i> , 2014, 16, 1.	0.2	3
359	Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation. <i>Current Problems in Cardiology</i> , 2014, 39, 319-344.	1.1	5
360	Measurement of Dabigatran in Standardly Used Clinical Assays, Whole Blood Viscoelastic Coagulation, and Thrombin Generation Assays. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 479-501.	0.7	29
361	Concerns over data in key dabigatran trial. <i>BMJ, The</i> , 2014, 349, g4747-g4747.	3.0	22
362	Dabigatran, bleeding, and the regulators. <i>BMJ, The</i> , 2014, 349, g4517-g4517.	3.0	70
363	Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. <i>Stroke</i> , 2014, 45, 2160-2236.	1.0	3,891
364	What is the Role of Renal Replacement Therapy in the Setting of Dabigatran Toxicity?. <i>Seminars in Dialysis</i> , 2014, 27, 223-226.	0.7	2
365	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society. <i>European Heart Journal</i> , 2014, 35, 2155-2179.	1.0	490
366	Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants—translating clinical trial data into practice. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2014, 40, 261-268.	0.6	2
367	Acute stroke in patients on new direct oral anticoagulants: how to manage, how to treat?. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1991-2001.	0.9	11
368	Benefit—Risk Assessment of Dabigatran in the Treatment of Stroke Prevention in Non-Valvular Atrial Fibrillation. <i>Drug Safety</i> , 2014, 37, 295-307.	1.4	3
369	Direct Oral Anticoagulants and Bleeding Risk (in Comparison to Vitamin K Antagonists and Heparins), and the Treatment of Bleeding. <i>Seminars in Hematology</i> , 2014, 51, 102-111.	1.8	17
370	Controversies regarding the new oral anticoagulants for stroke prevention in patients with atrial fibrillation. <i>Vascular Medicine</i> , 2014, 19, 190-204.	0.8	11
371	Risk of major bleeding and the standard doses of dabigatran. <i>European Journal of Internal Medicine</i> , 2014, 25, e73-e75.	1.0	4
372	Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation. <i>Clinical Therapeutics</i> , 2014, 36, 192-210.e20.	1.1	74
373	Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: A French payer perspective. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 381-390.	0.7	16
374	Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. <i>The Cochrane Library</i> , 2016, 2016, CD009893.	1.5	44
376	New oral anticoagulants—what the cardiothoracic surgeon needs to know. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 148, 1794-1801.e1.	0.4	11

#	ARTICLE	IF	CITATIONS
377	Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2014, 112, 981-988.	1.8	99
378	Assessment of a New Method of Warfarin Management vs the New Oral Anticoagulants and Conventional Warfarin Management in Atrial Fibrillation. <i>Chest</i> , 2014, 146, 532A.	0.4	0
379	Response. <i>Chest</i> , 2015, 147, e71-e72.	0.4	0
381	Efficacy and Safety of Dabigatran Etxilate vs. Warfarin in Asian RE-LY Patients According to Baseline Renal Function or CHADS ₂ Score. <i>Circulation Journal</i> , 2015, 79, 2138-2147.	0.7	14
382	Cardiological Aspects of Stroke Prevention. <i>Circulation Journal</i> , 2015, 79, 271-277.	0.7	8
383	Anticoagulants for stroke prevention in patients with atrial fibrillation. <i>British Journal of Neuroscience Nursing</i> , 2015, 11, 31-37.	0.1	0
384	The Association of Direct Thrombin Inhibitor Anticoagulants With Cardiac Thromboses. <i>Chest</i> , 2015, 147, 21-24.	0.4	16
385	Race/Ethnicity in Atrial Fibrillation Stroke: Epidemiology and Pharmacotherapy. <i>Journal of the National Medical Association</i> , 2015, 107, 59-67.	0.6	1
386	A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: balancing the risks and benefits. <i>Thrombosis Journal</i> , 2015, 13, 29.	0.9	1
387	The Real-World Treatment of Hemorrhages Associated With Dabigatran and Rivaroxaban. <i>Critical Pathways in Cardiology</i> , 2015, 14, 53-61.	0.2	15
388	Novel oral anticoagulants in atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 512-519.	0.6	10
390	Clinical utility of dabigatran in United Arab Emirates. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2015, 36, 1290-1298.	0.5	2
391	Old and new oral anticoagulants for secondary stroke prevention in atrial fibrillation. <i>Italian Journal of Medicine</i> , 2015, 9, 314.	0.2	0
392	Surgical Treatment of Traumatic Intracranial Hemorrhage in Patients with Novel Oral Anticoagulant (NOAC) Administration : A Report of Three Cases. <i>Japanese Journal of Neurosurgery</i> , 2015, 24, 327-333.	0.0	0
393	Use of oral anticoagulants in African-American and Caucasian patients with atrial fibrillation: is there a treatment disparity?. <i>Journal of Multidisciplinary Healthcare</i> , 2015, 8, 217.	1.1	13
394	Current and emerging strategies in the management of venous thromboembolism: benefit–risk assessment of dabigatran. <i>Vascular Health and Risk Management</i> , 2015, 11, 271.	1.0	7
395	Gastrointestinal Bleeding with Dabigatran, a Comparative Study with Warfarin: A Multicenter Experience. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2015, 65, 205.	0.2	7
396	Utilization of Dabigatran for Atrial Fibrillation at 3 Tertiary Care Centres. <i>Canadian Journal of Hospital Pharmacy</i> , 2015, 68, 369-77.	0.1	3

#	ARTICLE	IF	CITATIONS
397	Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation. <i>Vascular Health and Risk Management</i> , 2015, 11, 317.	1.0	11
398	Net Clinical Benefit of Oral Anticoagulants: A Multiple Criteria Decision Analysis. <i>PLoS ONE</i> , 2015, 10, e0124806.	1.1	19
399	Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1113-1126.	1.8	59
400	Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2) Tj ETQq1 1 0.784314 rgBT /Over	1.0	11
401	Hospital Admissions, Costs, and 30-Day Readmissions Among Newly Diagnosed Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran Etxilate or Warfarin. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015, 21, 1039-1053.	0.5	6
402	A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. <i>Thrombosis and Haemostasis</i> , 2015, 113, 943-951.	1.8	231
403	Non-Vitamin K Antagonist Oral Anticoagulants: New Choices for Patient Management in Atrial Fibrillation. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 323-335.	1.0	9
404	Safety and efficacy of switching from low molecular weight heparin to dabigatran in patients undergoing elective total hip or knee replacement surgery. <i>Thrombosis Journal</i> , 2015, 13, 37.	0.9	5
405	Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management—a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2017, 38, ehv676.	1.0	48
407	A novel approach indirectly comparing benefit—risk balance across anti-thrombotic therapies in patients with atrial fibrillation. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 15-28.	1.4	15
408	Selection of Warfarin or One of the New Oral Antithrombotic Agents for Long-Term Prevention of Stroke among Persons with Atrial Fibrillation. <i>Current Treatment Options in Neurology</i> , 2015, 17, 331.	0.7	1
409	Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran. <i>Clinical Toxicology</i> , 2015, 53, 156-163.	0.8	29
410	Role of new oral antithrombin in management of thrombophilia presented with multiple infarctions (cerebral, myocardial and pulmonary embolism). <i>The Egyptian Journal of Chest Diseases and Tuberculosis</i> , 2015, 64, 255-259.	0.1	2
412	Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 45-62.	1.0	6
413	Stroke and Systemic Embolism Prevention in Patients with Atrial Fibrillation in Belgium: Comparative Cost Effectiveness of New Oral Anticoagulants and Warfarin. <i>Clinical Drug Investigation</i> , 2015, 35, 109-119.	1.1	23
414	Non-vitamin K oral anticoagulants in atrial fibrillation: Where are we now?. <i>Trends in Cardiovascular Medicine</i> , 2015, 25, 315-336.	2.3	18
415	Design, synthesis, biological evaluation and molecular docking of novel dabigatran derivatives as potential thrombin inhibitors. <i>RSC Advances</i> , 2015, 5, 23737-23748.	1.7	12
416	Determinants of oral anticoagulation control in new warfarin patients: analysis using data from Clinical Practice Research Datalink. <i>Thrombosis Research</i> , 2015, 136, 250-260.	0.8	47

#	ARTICLE	IF	CITATIONS
417	Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. <i>International Journal of Cardiology</i> , 2015, 196, 127-131.	0.8	74
418	Critical Appraisal of Network Meta-Analyses Evaluating the Efficacy and Safety of New Oral Anticoagulants in Atrial Fibrillation Stroke Prevention Trials. <i>Value in Health</i> , 2015, 18, 234-249.	0.1	24
419	Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials. <i>American Journal of Medicine</i> , 2015, 128, 1007-1014.e2.	0.6	32
420	New oral anticoagulants versus vitamin K antagonists for treatment of acute venous thromboembolism: do they really increase the incidence of myocardial infarction?. <i>Internal and Emergency Medicine</i> , 2015, 10, 493-498.	1.0	1
421	Antithrombotic treatment for stroke prevention in atrial fibrillation: The Asian agenda. <i>International Journal of Cardiology</i> , 2015, 191, 244-253.	0.8	25
422	Systematic review of cost-effectiveness analyses of novel oral anticoagulants for stroke prevention in atrial fibrillation. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2015, 34, 179-191.	0.2	24
423	Synthesis and Biological Evaluation of Some New 2,5-Substituted 1-Ethyl-4-benzimidazole Fluorinated Derivatives as Direct Thrombin Inhibitors. <i>Archiv Der Pharmazie</i> , 2015, 348, 353-365.	2.1	8
424	Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities. <i>Drugs</i> , 2015, 75, 1627-1644.	4.9	37
425	Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: Results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial. <i>American Heart Journal</i> , 2015, 170, 669-674.	1.2	19
426	A cost-effectiveness analysis of screening for silent atrial fibrillation after ischaemic stroke. <i>Europace</i> , 2015, 17, 207-214.	0.7	50
427	Revisão sistemática das análises custo-efetividade dos novos anticoagulantes orais na prevenção do acidente vascular cerebral na fibrilhação auricular. <i>Revista Portuguesa De Cardiologia</i> , 2015, 34, 179-191.	0.2	28
428	Apixaban and risk of myocardial infarction: meta-analysis of randomized controlled trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 1-11.	1.0	7
429	Safety and efficacy of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: a Bayesian meta-analysis approach. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 7-20.	1.0	23
430	Atrial Fibrillation Management in Older Heart Failure Patients: A Complex Clinical Problem. <i>Heart International</i> , 2016, 11, heartint.500023.	0.4	10
431	Dabigatran treatment simulation in patients undergoing maintenance haemodialysis. <i>Thrombosis and Haemostasis</i> , 2016, 115, 562-569.	1.8	9
432	Dabigatran approaching the realm of heparin-induced thrombocytopenia. <i>Blood Research</i> , 2016, 51, 77.	0.5	8
433	Direct Oral Anticoagulants in Emergency Trauma Admissions. <i>Deutsches A&#x0308;rztblatt International</i> , 2016, 113, 575-82.	0.6	35
434	Minimizing bleeding risk in patients receiving direct oral anticoagulants for stroke prevention. <i>International Journal of General Medicine</i> , 2016, Volume 9, 337-347.	0.8	12

#	ARTICLE	IF	CITATIONS
435	Challenges from Variation across Regions in Cost Effectiveness Analysis in Multi-Regional Clinical Trials. <i>Frontiers in Pharmacology</i> , 2016, 7, 371.	1.6	0
436	Systematic review and network meta-analysis of stroke-prevention treatments in patients with atrial fibrillation. <i>Clinical Pharmacology: Advances and Applications</i> , 2016, Volume 8, 93-107.	0.8	35
437	Comparison of treatment effect estimates of non-vitamin K antagonist oral anticoagulants versus warfarin between observational studies using propensity score methods and randomized controlled trials. <i>European Journal of Epidemiology</i> , 2016, 31, 541-561.	2.5	21
438	Dabigatran in clinical practice: Contemporary overview of the evidence. <i>International Journal of Cardiology</i> , 2016, 220, 417-428.	0.8	9
439	Acenocoumarol vs. low-dose dabigatran in real-world patients discharged after ischemic stroke. <i>Blood Coagulation and Fibrinolysis</i> , 2016, 27, 185-189.	0.5	1
440	Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis. <i>Science Translational Medicine</i> , 2016, 8, 367ra168.	5.8	32
444	Consideraciones clínicas sobre la posología de los anticoagulantes orales de acción directa. <i>Revista Clinica Espanola</i> , 2016, 216, 384-392.	0.2	0
445	Observational study of dabigatran etexilate 150 mg in patients with moderate renal impairment undergoing elective total hip or knee replacement. <i>Thrombosis Research</i> , 2016, 143, 103-110.	0.8	4
446	Molecular design, synthesis and anticoagulant activity evaluation of fluorinated dabigatran analogues. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 2739-2753.	1.4	8
447	Real Data on Effectiveness, Tolerability and Safety of New Oral Anticoagulant Agents: Focus on Dabigatran. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2016, 23, 115-122.	1.0	1
448	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2016, 37, 2129-2200.	1.0	13,008
449	¿Son los nuevos anticoagulantes orales iguales a las antivitaminas K para la isquemia aguda de los miembros inferiores? Revisión sistemática de la evidencia. <i>Angiología</i> , 2016, 68, 123-126.	0.0	0
451	North American Thrombosis Forum, AF Action Initiative Consensus Document. <i>American Journal of Medicine</i> , 2016, 129, S1-S29.	0.6	24
452	The discovery of dabigatran etexilate for the treatment of venous thrombosis. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 717-731.	2.5	6
453	Novel oral anticoagulants for the secondary prevention of cerebral ischemia: a network meta-analysis. <i>Therapeutic Advances in Neurological Disorders</i> , 2016, 9, 359-368.	1.5	25
454	Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience. <i>American Journal of Medicine</i> , 2016, 129, S33-S40.	0.6	74
455	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 50, e1-e88.	0.6	754
456	Hierarchical models for multiple, rare outcomes using massive observational healthcare databases. <i>Statistical Analysis and Data Mining</i> , 2016, 9, 260-268.	1.4	11

#	ARTICLE	IF	CITATIONS
457	Bleeding with direct oral anticoagulants vs warfarin: clinical experience. <i>American Journal of Emergency Medicine</i> , 2016, 34, 3-8.	0.7	25
458	A Prospective, Randomized, Open-Label Study to Evaluate Two Management Strategies for Gastrointestinal Symptoms in Patients Newly on Treatment with Dabigatran. <i>Cardiology and Therapy</i> , 2016, 5, 187-201.	1.1	9
459	Chronic anticoagulation in non-valvular atrial fibrillation: Where things stand. <i>International Journal of Cardiology</i> , 2016, 222, 615-619.	0.8	5
460	Clinical considerations on the posology of direct oral anticoagulants. <i>Revista Clínica Española</i> , 2016, 216, 384-392.	0.3	0
461	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 891-975.	2.9	5,272
462	The Association Between Bleeding and the Incidence of Warfarin Discontinuation in Patients with Atrial Fibrillation. <i>Cardiovascular Therapeutics</i> , 2016, 34, 94-99.	1.1	3
463	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Heart Journal</i> , 2016, 37, 2893-2962.	1.0	5,689
464	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>Europace</i> , 2016, 18, 1609-1678.	0.7	3,523
465	Beneficial Effect of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation—Results of the J-RHYTHM Registry 2. <i>Circulation Journal</i> , 2016, 80, 843-851.	0.7	42
466	Association between Renal Function and Bleeding Risk for Dabigatran after Switching from Warfarin. <i>American Journal of Nephrology</i> , 2016, 44, 11-18.	1.4	9
467	Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents. <i>Circulation</i> , 2016, 134, 248-261.	1.6	98
469	Electronic Alert System for Improving Stroke Prevention Among Hospitalized Oral Anticoagulation-Naïve Patients With Atrial Fibrillation: A Randomized Trial. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	29
470	Intracranial hemorrhage during administration of a novel oral anticoagulant. <i>Journal of Rural Medicine: JRM</i> , 2016, 11, 69-72.	0.2	3
471	Dabigatran in real-world atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2016, 116, 754-763.	1.8	78
472	Rationale and design of the ODIn-AF Trial: randomized evaluation of the prevention of silent cerebral thromboembolism by oral anticoagulation with dabigatran after pulmonary vein isolation for atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2016, 105, 95-105.	1.5	10
473	Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, .	2.1	17
474	Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 201-214.	1.3	18
475	NOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis. <i>Open Heart</i> , 2016, 3, e000279.	0.9	85

#	ARTICLE	IF	CITATIONS
476	Individualized approaches to thromboprophylaxis in atrial fibrillation. <i>American Heart Journal</i> , 2016, 173, 143-158.	1.2	12
477	Atrial fibrillation and arterial hypertension: A common duet with dangerous consequences where the renin angiotensin-aldosterone system plays an important role. <i>International Journal of Cardiology</i> , 2016, 206, 71-76.	0.8	36
478	Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. <i>International Journal of Cardiology</i> , 2016, 204, 88-94.	0.8	73
479	Direct Oral Anticoagulants for the Management of Thromboembolic Disorders. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 605-616.	0.7	23
480	Management Overview: Taking a Patient with Intracranial Hemorrhage Related to Direct Oral Anticoagulants to the Operating Room. <i>World Neurosurgery</i> , 2016, 90, 262-267.	0.7	6
481	How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation. <i>Annals of Hematology</i> , 2016, 95, 437-449.	0.8	56
482	Meta-analysis and adjusted indirect comparison of direct oral anticoagulants in prevention of acute limb ischemia in patients with atrial fibrillation. <i>Current Medical Research and Opinion</i> , 2016, 32, 1167-1173.	0.9	9
483	Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation. <i>Heart Failure Clinics</i> , 2016, 12, 257-271.	1.0	8
484	Clinical and economic consequences of using dabigatran or rivaroxaban in patients with non-valvular atrial fibrillation. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2016, 35, 141-148.	0.2	5
485	Risk of Myocardial Infarction in Patients with Long-Term Non-Vitamin K Antagonist Oral Anticoagulant Treatment. <i>Progress in Cardiovascular Diseases</i> , 2016, 58, 483-494.	1.6	27
486	Comparison of Watchman device with new oral anti-coagulants in patients with atrial fibrillation: A network meta-analysis. <i>International Journal of Cardiology</i> , 2016, 205, 17-22.	0.8	28
487	Molecular modeling studies, synthesis and biological evaluation of dabigatran analogues as thrombin inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 73-84.	1.4	13
488	Cardiovascular causes of emergency neurology presenting to an ICU. <i>Perfusion (United Kingdom)</i> , 2016, 31, 271-280.	0.5	2
489	Coagulation assessment with the new generation of oral anticoagulants. <i>Emergency Medicine Journal</i> , 2016, 33, 423-430.	0.4	58
490	Practical Considerations for the Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 5-19.	0.7	9
492	Reversing the anticoagulation effects of dabigatran. <i>Hospital Practice (1995)</i> , 2017, 45, 29-38.	0.5	13
493	Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation. <i>Drugs</i> , 2017, 77, 331-344.	4.9	19
495	Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	0.9	27

#	ARTICLE	IF	CITATIONS
496	Triple antithrombotic therapy, including NAO, in patients after coronary stenting. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, e125-e128.	0.6	0
497	Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 365-379.	1.0	89
498	Dabigatran in nonvalvular atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 467-477.	0.6	7
499	Oral Anticoagulation Therapy. , 2017, , .		1
500	Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany – A national case collection. <i>International Journal of Stroke</i> , 2017, 12, 383-391.	2.9	80
501	Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF Registry. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 657-665.	0.9	19
502	Direct oral anticoagulants and cardiovascular prevention in patients with nonvalvular atrial fibrillation. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 67-77.	0.9	7
503	Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan. <i>Clinical Drug Investigation</i> , 2017, 37, 285-293.	1.1	14
504	Predicted risk of stroke and bleeding and use of oral anticoagulants in atrial fibrillation: Danish nationwide temporal trends 2011–2016. <i>Thrombosis Research</i> , 2017, 160, 19-26.	0.8	3
505	All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAf) Newly Treated with Dabigatran or Warfarin. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 481-492.	1.0	10
507	Efficacy of non-vitamin-K antagonist oral anticoagulants for intracardiac thrombi resolution in nonvalvular atrial fibrillation. <i>Drug Discovery Today</i> , 2017, 22, 1565-1571.	3.2	6
508	Bleeding events associated with a low dose (110Âmg) versus a high dose (150Âmg) of dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 83.	0.7	5
509	Special considerations for therapeutic choice of non-vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillation. <i>Clinical Cardiology</i> , 2017, 40, 126-131.	0.7	21
510	Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 682-690.	2.4	47
511	Use of direct oral anticoagulants in patients with nonvalvular atrial fibrillation according to clinical profile. <i>Future Cardiology</i> , 2017, 13, 49-64.	0.5	1
512	Financial Impact of Direct-Acting Oral Anticoagulants in Medicaid: Budgetary Assessment Based on Number Needed to Treat. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 203-214.	1.0	4
513	Antiplatelet and Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Coronary Stenting. <i>Interventional Cardiology Clinics</i> , 2017, 6, 91-117.	0.2	4
514	Practical Considerations for the Nonvitamin K Antagonist Oral Anticoagulants. <i>Cardiology</i> , 2017, 136, 115-124.	0.6	17

#	ARTICLE	IF	CITATIONS
516	Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017, 1, 202-215.	1.0	14
517	Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice. <i>Annals of Internal Medicine</i> , 2017, 167, 845.	2.0	37
518	Reducing the risk of stroke in elderly patients with non-valvular atrial fibrillation: a practical guide for clinicians. <i>Clinical Interventions in Aging</i> , 2017, Volume 12, 175-187.	1.3	10
519	First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab. <i>Case Reports in Cardiology</i> , 2017, 2017, 1-3.	0.1	8
520	Stroke Prevention with Oral Anticoagulants: Summary of the Evidence and Efficacy Measures as an Aid to Treatment Choices. <i>Cardiology and Therapy</i> , 2018, 7, 15-24.	1.1	21
521	Antithrombotic Therapy for Patients with Atrial Fibrillation. , 2018, , 217-238.		0
522	Design and rationale for the DIVERSITY study: An open-label, randomized study of dabigatran etexilate for pediatric venous thromboembolism. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 347-356.	1.0	12
523	Cardiovascular Drugs and Hemostasis. , 2018, , 561-589.		0
524	Clinical Trials for Atrial Fibrillation-What Do We Know?. , 2018, , 630-642.		0
525	Atrial fibrillation patient preferences for oral anticoagulation and stroke knowledge: Results of a conjoint analysis. <i>Clinical Cardiology</i> , 2018, 41, 855-861.	0.7	31
526	Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or Dabigatran. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1878-1889.	1.1	18
527	Use of Guidelines for Reducing Stroke Risk in Patients With Nonvalvular Atrial Fibrillation: A Review From a Latin American Perspective. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 22-32.	0.7	11
528	The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands. <i>Journal of Medical Economics</i> , 2018, 21, 38-46.	1.0	3
529	Use of newly designed graphs for depicting network meta-analyses. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 681-683.	0.6	0
530	Letters to the Editor. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2018, 31, 1-3.	0.1	0
531	Factors associated with availability of anticoagulation reversal agents in rural and community emergency departments. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 72-77.	0.5	9
532	Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease. <i>Stroke</i> , 2018, 49, 2844-2850.	1.0	9
533	Assessment of Outcomes of Treatment With Oral Anticoagulants in Patients With Atrial Fibrillation and Multiple Chronic Conditions. <i>JAMA Network Open</i> , 2018, 1, e182870.	2.8	19

#	ARTICLE	IF	CITATIONS
534	Bleeding in patients receiving non-vitamin K oral anticoagulants: clinical trial evidence. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2018, 12, 361-380.	1.0	17
535	Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2018, 169, 774.	2.0	17
536	The Effects of Dabigatran and Rivaroxaban on Markers of Polymorphonuclear Leukocyte Activation. <i>Pharmaceuticals</i> , 2018, 11, 46.	1.7	5
537	LMU Munich: platelet inhibition novel aspects on platelet inhibition and function. <i>Clinical Research in Cardiology</i> , 2018, 107, 30-39.	1.5	23
538	Factors influencing dabigatran or warfarin medication persistence in patients with nonvalvular atrial fibrillation. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 685-691.	0.6	4
539	Direct-Acting Oral Anticoagulants in Critically Ill Patients. <i>Chest</i> , 2019, 156, 604-618.	0.4	11
540	<p>Using non-vitamin K oral anticoagulants in specific patient populations: a study of Korean cases</p>. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 1183-1206.	0.9	6
541	Oral anticoagulation in very elderly patients with atrial fibrillation: Results from the prospective multicenter START2-REGISTER study. <i>PLoS ONE</i> , 2019, 14, e0216831.	1.1	19
542	Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 171-180.	1.4	46
543	The Direct Thrombin Inhibitors Dabigatran and Lepirudin Inhibit GPIIb/3a-Mediated Platelet Aggregation. <i>Thrombosis and Haemostasis</i> , 2019, 119, 916-929.	1.8	14
544	Clinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 487-494.	1.0	14
545	Comparative Effectiveness and Safety of Rivaroxaban in Adults With Nonvalvular Atrial Fibrillation. <i>American Journal of Therapeutics</i> , 2019, 26, e679-e703.	0.5	4
546	The Basics of Antithrombotic Medications. <i>Topics in Geriatric Rehabilitation</i> , 2019, 35, 55-71.	0.2	0
547	Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 313.	1.8	91
549	Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation. <i>Circulation</i> , 2019, 139, 604-616.	1.6	117
550	Educational Impact on Apixaban Adherence in Atrial Fibrillation (the AEGEAN STUDY): A Randomized Clinical Trial. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 61-71.	1.0	22
551	Comparative Clinical Outcomes of Edoxaban in Adults With Nonvalvular Atrial Fibrillation. <i>American Journal of Therapeutics</i> , 2020, 27, e270-e285.	0.5	2
552	Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial. <i>Advances in Therapy</i> , 2020, 37, 420-430.	1.3	6

#	ARTICLE	IF	CITATIONS
553	Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese Volunteers: A Pharmacokinetics, Pharmacodynamics, and Safety Study. <i>Advances in Therapy</i> , 2020, 37, 3916-3928.	1.3	0
554	Drugs, Devices, and Procedural Therapies to Prevent Recurrent Cardiogenic Embolic Stroke. , 2020, , 337-383.		0
555	A Review of the Medical Challenges of Using Direct Oral Anticoagulants in Real-World Practice. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 793-802.	0.8	0
556	Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germanyâ€”Updated series of 120 cases. <i>International Journal of Stroke</i> , 2020, 15, 609-618.	2.9	54
557	The NCDR Left Atrial Appendage Occlusion Registry. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1503-1518.	1.2	237
559	Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: Potential role of antiplatelet agents. <i>Blood Reviews</i> , 2021, 45, 100694.	2.8	87
560	Noncanonical Effects of Oral Thrombin and Factor Xa Inhibitors in Platelet Activation and Arterial Thrombosis. <i>Thrombosis and Haemostasis</i> , 2021, 121, 122-130.	1.8	8
561	Comparative effectiveness and safety of highâ€”dose rivaroxaban and apixaban for atrial fibrillation: A propensity scoreâ€”matched cohort study. <i>Pharmacotherapy</i> , 2021, 41, 379-393.	1.2	5
562	The Impact of ABCB1 and CES1 Polymorphisms on Dabigatran Pharmacokinetics in Healthy Chinese Subjects. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 477-485.	0.4	9
563	Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation in Real Clinical Practice: in Appropriate Dose Reductions. <i>Rational Pharmacotherapy in Cardiology</i> , 2021, 17, 206-211.	0.3	1
564	Can clinical pharmacists utilize telehealth to double the safety and efficacy of oral anticoagulation while reducing health care costs and improving patient satisfaction in patients with atrial fibrillation?. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2021, 4, 969-977.	0.5	0
565	Elderly patient with atrial fibrillation and coronary risks. <i>Atherothrombosis</i> , 2021, , 51-57.	0.1	0
566	2020 Clinical guidelines for Atrial fibrillation and atrial flutter. <i>Russian Journal of Cardiology</i> , 2021, 26, 4594.	0.4	89
567	Optimal choice of prophylactic anticoagulant therapy for nonvalvular atrial fibrillation in the context of COVID-19 pandemic. <i>Russian Journal of Cardiology</i> , 2021, 26, 4607.	0.4	0
568	Cardiovascular Drugs and Hemostasis. , 2022, , 701-729.		1
569	Atrial fibrillation in low- and middle-income countries: a narrative review. <i>European Heart Journal Supplements</i> , 2020, 22, O61-O77.	0.0	22
570	Dabigatran for Stroke Prevention in Nonvalvular Atrial Fibrillation: Answers to Challenging â€œReal-Worldâ€œ Questions. <i>Thrombosis</i> , 2012, 2012, 1-10.	1.4	4
572	Recent advances in the understanding and management of atrial fibrillation: a focus on stroke prevention. <i>F1000Research</i> , 2016, 5, 2887.	0.8	5

#	ARTICLE	IF	CITATIONS
573	Edoxaban in the Evolving Scenario of Non Vitamin K Antagonist Oral Anticoagulants Imputed Placebo Analysis and Multiple Treatment Comparisons. PLoS ONE, 2014, 9, e100478.	1.1	24
574	Illustrating the Sense of a Network Meta-Analysis by Means of Dedicated Plots: A Way for Making It Conceptually Easier and More Immediately Understandable. Journal of Clinical Medicine Research, 2018, 10, 732-735.	0.6	2
575	Anticoagulation in Atrial Fibrillation. Arrhythmia and Electrophysiology Review, 2012, 1, 12.	1.3	2
576	Cost Implications of Formulary Decisions on Oral Anticoagulants in Nonvalvular Atrial Fibrillation. Journal of Managed Care Pharmacy, 2013, 19, 789-798.	2.2	18
577	Novel oral anticoagulants for stroke prevention in atrial fibrillation: a focus on the older patient. International Journal of General Medicine, 2013, 6, 167.	0.8	16
578	Novel Direct Anticoagulants and Atherosclerosis. Current Vascular Pharmacology, 2018, 17, 29-34.	0.8	3
579	Bleeding, Vertebral Fractures and Vascular Calcifications in Patients Treated with Warfarin: Hope for Lower Risks with Alternative Therapies. Current Vascular Pharmacology, 2011, 9, 763-769.	0.8	22
580	Trials of Novel Oral Anticoagulants for Stroke Prevention In Patients with Non-valvular Atrial Fibrillation. Current Cardiology Reviews, 2014, 10, 297-302.	0.6	11
581	Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technology Assessment, 2017, 21, 1-386.	1.3	117
582	2018 KHRS Guidelines for Stroke Prevention Therapy in Korean Patients with Nonvalvular Atrial Fibrillation. Korean Journal of Medicine, 2018, 93, 87-109.	0.1	8
584	Are the novel anticoagulants better than warfarin for patients with atrial fibrillation?. Journal of Thoracic Disease, 2015, 7, 165-71.	0.6	44
585	The Nonvitamin K Antagonist Oral Anticoagulants and Atrial Fibrillation: Challenges and Considerations. Journal of Atrial Fibrillation, 2017, 9, 1547.	0.5	4
586	The current approach of atrial fibrillation management. Avicenna Journal of Medicine, 2016, 06, 8-16.	0.3	31
587	Left atrial appendage closure for stroke prevention in non-valvular atrial fibrillation: rationale, devices in clinical development and insights into implantation techniques. EuroIntervention, 2014, 10, 497-504.	1.4	40
588	A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients. EuroIntervention, 2013, 8, 1052-1060.	1.4	54
589	Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland. Swiss Medical Weekly, 2013, 143, w13732.	0.8	20
591	ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation?. Cardiology Journal, 2012, 19, 4-10.	0.5	19
593	Prevalence of oral anticoagulation in atrial fibrillation. Clinics, 2014, 69, 615-620.	0.6	14

#	ARTICLE	IF	CITATIONS
594	Effectiveness and Safety of Dabigatran Compared to Vitamin K Antagonists in Non-Asian Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis. <i>Clinical Drug Investigation</i> , 2021, 41, 941-953.	1.1	5
595	Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Myocardial Infarction in Patients with Atrial Fibrillation with or without Percutaneous Coronary Interventions: A Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2021, 11, 1013.	1.1	2
596	Fact-Finding Survey of Antithrombotic Treatment for Prevention of Cerebral and Systemic Thromboembolism in Patients with Non-Valvular Atrial Fibrillation in 9 Countries of the Asia-Pacific Region. <i>Journal of Arrhythmia</i> , 2011, 27, PGS.	0.5	1
597	New anticoagulant commentary from a basic viewpoint. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2011, 22, 151-155.	0.1	0
599	Title is missing!. <i>Japanese Journal of Electrocardiology</i> , 2011, 31, 287-291.	0.0	0
600	Evaluation of the Acute Coronary Syndrome Safety Profile of Dabigatran Etxilate in Patients Undergoing Major Orthopaedic Surgery: Findings From Four Phase III Trials. <i>Blood</i> , 2011, 118, 2309-2309.	0.6	0
601	Dabigatran for prophylaxis of thromboembolic events in patients with atrial fibrillation. <i>Research Reports in Clinical Cardiology</i> , 0, , 11.	0.2	0
604	A paradigm shift of the prevention of cardiogenic cerebral embolism. <i>Japanese Journal of Electrocardiology</i> , 2012, 32, 202-204.	0.0	0
605	Anticoagulation for atrial fibrillation. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2012, 23, 8-15.	0.1	0
606	Prevention of thromboembolic complications of atrial fibrillation: Current aspects and perspective. <i>Srce I Krvni Sudovi</i> , 2012, 31, 68-76.	0.1	1
608	New Anticoagulation Medications for Atrials Fibrillation. <i>Journal of Developing Drugs</i> , 2013, 02, .	0.9	0
609	Atrial fibrillation and stroke in the perspective of new oral anticoagulants. <i>Türk Beyin Damar Hastalıkları Dergisi</i> , 2013, 19, 35-45.	0.1	0
610	Current Dose of Dabigatran cannot Suit Every Patient--Study from STACIN Registry-. <i>Japanese Journal of Electrocardiology</i> , 2013, 33, 59-64.	0.0	0
611	Novel Oral Anticoagulants for Stroke Prevention in Patients with Non-valvular Atrial Fibrillation. , 2014, , 55-89.		0
613	Effect of Changing the Method of Taking Dabigatran on Gastrointestinal Adverse Events. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , 2014, 40, 618-624.	0.0	1
614	Does the Role of Generalists in Stroke Prevention Change with the Novel Oral Anticoagulants?. <i>Japanese Journal of Electrocardiology</i> , 2014, 34, 167-174.	0.0	0
615	Dabigatran-etaxil: Nová schvlená indikace IČby a prevence rekurence hluboké tromboembolie. <i>Cor Et Vasa</i> , 2014, 56, 582-585.	0.1	0

#	ARTICLE	IF	CITATIONS
617	Clinical trial and the real world. No Junkan Taisha = Cerebral Blood Flow and Metabolism, 2015, 26, 63-66.	0.1	0
618	Advances in Anticoagulants. , 2016, , 819-825.		0
619	Safety and Efficacy of New Oral Anticoagulants in Patients with Atrial Fibrillation: A Literature Review. Journal of Diabetic Complications & Medicine, 2016, 01, .	0.2	0
620	Patient with Concomitant Stable Coronary Artery Disease. , 2017, , 69-73.		0
621	Defibrillation Testing During ICD Implantation â€œ Should we or Should we Not?. Journal of Atrial Fibrillation, 2017, 9, 1508.	0.5	2
622	OBSOLETE: Clinical Trials for Atrial Fibrillation - What do we know? . , 2018, , .		0
623	MERKEZÄ°MÄ°ZDE NON- VALVÄœLER ATRÄ°YAL FÄ°BRÄ°LASYON TANISI ALMIÄž HASTALARIN DEMOGRAFÄ°K Ä–ZELLÄ°KLERÄ° Ä°LE ORAL ANTÄ°KOAGÄœLASYON TERCÄ°HLERÄ°NÄ°N RETROSPEKTÄ°F OLARAK DEÄžERLENDÄ°RÄ°LMESÄ° RETROSPECTIVE EVALUATION OF ORAL ANTICOAGULATION PREFERENCES AND DEMOGRAPHIC CHARACTERISTICS OF THE PATÄ°ENTS WÄ°TH NON-VALVULAR ATRIAL FIBRILLATION IN OUR CENTER. Bozok TÄ±p Dergisi, 0, , .	0.0	0
624	CHOICE OF DIRECT ORAL ANTICOAGULANTS BASED ON THE INDIVIDUAL APPROACH. Translational Medicine, 2019, 5, 10-22.	0.1	0
625	Network meta-analysis: a new analysis tool of the experimental evidence. Minerva Medica, 2019, 110, 173-175.	0.3	0
626	(Cost-effectiveness analysis of first-line NOAC prevention of stroke and systemic embolism in patients) Tj ETQq1 1 0.784314 3gBT /Over 0,1	0.1	0
627	Direct oral anticoagulants: A new chapter in anticoagulation therapy. Arhiv Za Farmaciju, 2020, 70, 249-268.	0.2	0
628	Central directions for reducing cardiovascular mortality: what can be changed today?. Russian Journal of Cardiology, 2020, 25, 3983.	0.4	12
630	Perioperative outcomes of interrupted anticoagulation in patients with non-valvular atrial fibrillation undergoing non-cardiac surgery. Yeungnam University Journal of Medicine, 2020, 37, 321-328.	0.7	2
631	Medication management of atrial fibrillation: emerging therapies for rhythm control and stroke prevention. P and T, 2011, 36, 518-28.	1.0	1
632	New oral anticoagulants for atrial fibrillation: are they worth the risk?. P and T, 2014, 39, 54-64.	1.0	10
633	Approach to the new oral anticoagulants in family practice: part 1: comparing the options. Canadian Family Physician, 2014, 60, 989-95.	0.1	12
634	Interrupting anticoagulation in patients with nonvalvular atrial fibrillation. P and T, 2014, 39, 858-80.	1.0	6
635	Comparison of Dabigatran vs. Warfarin in Acute Vnous Thromboemboly: Systematic Review. Iranian Journal of Pharmaceutical Research, 2016, 15, 611-7.	0.3	2

#	ARTICLE	IF	CITATIONS
636	The Cost Effectiveness of LAA Exclusion. Journal of Atrial Fibrillation, 2016, 8, 1374.	0.5	2
637	Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation With Direct Oral Anticoagulants. Is One Of These Not Like The Others?. Journal of Atrial Fibrillation, 2016, 9, 1481.	0.5	5
638	Choosing Non-Vitamin K Antagonist Oral Anticoagulants: Practical Considerations We Need to Know. Ochsner Journal, 2016, 16, 531-541.	0.5	5
639	Comparative Effectiveness and Safety of Low-Dose Oral Anticoagulants in Patients With Atrial Fibrillation. Frontiers in Pharmacology, 2021, 12, 812018.	1.6	4
640	MEDEX South Carolina: a progress report. The Journal of the South Carolina Medical Association, 1975, 71, 337-8.	0.0	0
641	<scp>JCS</scp>/<scp>JHRS</scp> 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. Journal of Arrhythmia, 2022, 38, 833-973.	0.5	8
642	JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. Circulation Journal, 2022, 86, 1790-1924.	0.7	49
645	New Anticoagulants for Stroke Prophylaxis in Atrial Fibrillation. American Journal of Cardiovascular Drugs, 2012, 12, 287-294.	1.0	2
646	Health economic evaluation of nation-wide screening programmes for atrial fibrillation in the Netherlands. European Heart Journal Quality of Care & Clinical Outcomes, 0, , .	1.8	2
647	EURASIAN CLINICAL RECOMMENDATIONS ON DIAGNOSIS AND TREATMENT OF ATRIAL FIBRILLATION. Eurasian Heart Journal, 2019, , 4-85.	0.2	13
649	Andexanet alfa (ONDEXXYA<sup>&A<sup>& for Intravenous Injection 200–.mg), a reversal agent for direct factor Xa inhibitors: pharmacological characteristics and clinical evidence. Folia Pharmacologica Japonica, 2023, 158, 89-100.	0.1	1